Blueprint Medicines Corporation (0HOJ.L)
USD 79.82
(3.41%)
USD 79.82
(3.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 918.64 Million USD | 9.99% |
| 2022 | 835.22 Million USD | 196.72% |
| 2021 | 281.49 Million USD | 13.36% |
| 2020 | 248.3 Million USD | 2.04% |
| 2019 | 243.33 Million USD | 100.91% |
| 2018 | 121.11 Million USD | 31.98% |
| 2017 | 91.76 Million USD | 31.63% |
| 2016 | 69.71 Million USD | 99.65% |
| 2015 | 34.91 Million USD | 140.89% |
| 2014 | 14.49 Million USD | 157.43% |
| 2013 | 5.63 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 886.5 Million USD | 0.36% |
| 2024 Q1 | 727.78 Million USD | -20.78% |
| 2024 Q2 | 883.31 Million USD | 21.37% |
| 2023 Q4 | 918.64 Million USD | 1.77% |
| 2023 Q1 | 806.07 Million USD | -3.49% |
| 2023 FY | 918.64 Million USD | 9.99% |
| 2023 Q2 | 795.31 Million USD | -1.33% |
| 2023 Q3 | 902.68 Million USD | 13.5% |
| 2022 FY | 835.22 Million USD | 196.72% |
| 2022 Q4 | 835.22 Million USD | 2.1% |
| 2022 Q3 | 818.08 Million USD | 83.97% |
| 2022 Q2 | 444.69 Million USD | 69.96% |
| 2022 Q1 | 261.64 Million USD | -7.05% |
| 2021 FY | 281.49 Million USD | 13.36% |
| 2021 Q3 | 230.23 Million USD | -4.07% |
| 2021 Q4 | 281.49 Million USD | 22.26% |
| 2021 Q1 | 225.36 Million USD | -9.24% |
| 2021 Q2 | 239.99 Million USD | 6.49% |
| 2020 Q2 | 236.09 Million USD | 2.34% |
| 2020 Q3 | 238.17 Million USD | 0.88% |
| 2020 FY | 248.3 Million USD | 2.04% |
| 2020 Q4 | 248.3 Million USD | 4.25% |
| 2020 Q1 | 230.69 Million USD | -5.2% |
| 2019 Q3 | 221.58 Million USD | 3.37% |
| 2019 Q1 | 200.45 Million USD | 65.5% |
| 2019 Q4 | 243.33 Million USD | 9.82% |
| 2019 Q2 | 214.35 Million USD | 6.93% |
| 2019 FY | 243.33 Million USD | 100.91% |
| 2018 Q1 | 93.59 Million USD | 1.99% |
| 2018 FY | 121.11 Million USD | 31.98% |
| 2018 Q2 | 112.18 Million USD | 19.86% |
| 2018 Q3 | 116.81 Million USD | 4.13% |
| 2018 Q4 | 121.11 Million USD | 3.68% |
| 2017 Q3 | 78.87 Million USD | 11.67% |
| 2017 Q2 | 70.63 Million USD | 9.63% |
| 2017 Q4 | 91.76 Million USD | 16.34% |
| 2017 FY | 91.76 Million USD | 31.63% |
| 2017 Q1 | 64.42 Million USD | -7.59% |
| 2016 Q3 | 70.13 Million USD | -5.16% |
| 2016 FY | 69.71 Million USD | 99.65% |
| 2016 Q4 | 69.71 Million USD | -0.6% |
| 2016 Q2 | 73.95 Million USD | -3.13% |
| 2016 Q1 | 76.35 Million USD | 118.65% |
| 2015 Q1 | 31.18 Million USD | 115.14% |
| 2015 FY | 34.91 Million USD | 140.89% |
| 2015 Q2 | 34.61 Million USD | 11.0% |
| 2015 Q3 | 37.14 Million USD | 7.3% |
| 2015 Q4 | 34.91 Million USD | -6.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | 14.49 Million USD | 0.0% |
| 2014 FY | 14.49 Million USD | 157.43% |
| 2013 FY | 5.63 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -47.214% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -628.508% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -48.718% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -247.004% |
| bluebird bio, Inc. | 424.62 Million USD | -116.342% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -1236.03% |
| Imunon, Inc. | 8.53 Million USD | -10668.992% |
| Editas Medicine, Inc. | 150.05 Million USD | -512.199% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 95.534% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 73.794% |
| Myriad Genetics, Inc. | 312.9 Million USD | -193.589% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 9.884% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -88.454% |
| Verastem, Inc. | 71.18 Million USD | -1190.498% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 98.666% |
| Waters Corporation | 3.47 Billion USD | 73.576% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 98.229% |
| Biogen Inc. | 12.04 Billion USD | 92.374% |
| Nektar Therapeutics | 267.04 Million USD | -244.001% |
| Perrigo Company plc | 6.04 Billion USD | 84.794% |
| Dynavax Technologies Corporation | 375.02 Million USD | -144.955% |
| Illumina, Inc. | 4.36 Billion USD | 78.959% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -2511.473% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -369.322% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -258.174% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -2363.373% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 51.396% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -1014.409% |
| Evolus, Inc. | 209.68 Million USD | -338.101% |
| Adicet Bio, Inc. | 37.12 Million USD | -2374.787% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -2183.7% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 87.074% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -39.022% |
| FibroGen, Inc. | 585.72 Million USD | -56.837% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 81.321% |
| OPKO Health, Inc. | 622.47 Million USD | -47.578% |
| Homology Medicines, Inc. | 118.53 Million USD | -675.009% |
| Geron Corporation | 146.12 Million USD | -528.659% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 77.32% |
| Exelixis, Inc. | 678.44 Million USD | -35.404% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -4476.957% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -7229.193% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -266.273% |
| Zoetis Inc. | 9.29 Billion USD | 90.117% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -131.245% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -1768.068% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 82.162% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1796.256% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 64.714% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 61.807% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -700.126% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 44.307% |
| Insmed Incorporated | 1.66 Billion USD | 44.719% |
| TG Therapeutics, Inc. | 169.08 Million USD | -443.301% |
| Incyte Corporation | 1.59 Billion USD | 42.306% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 22.517% |